Quantcast

Latest Metered-dose inhaler Stories

2011-07-21 12:30:19

Schroeder Institute researchers raise questions about safety, usage and future implications of new nicotine delivery products Devices marketed as "electronic cigarettes" are in reality crude drug delivery systems for refined nicotine, posing unknown risks with little new benefits to smokers, according to tobacco control experts. In a "Perspective" published today in the New England Journal of Medicine, researchers from the Legacy's Steven A. Schroeder National Institute for Tobacco Research...

2011-07-20 16:00:00

WASHINGTON, July 20, 2011 /PRNewswire-USNewswire/ -- Devices marketed as "electronic cigarettes" are in reality crude drug delivery systems for refined nicotine, posing unknown risks with little new benefits to smokers, according to tobacco control experts. (Logo: http://photos.prnewswire.com/prnh/20101101/DC86294LOGO) In a "Perspective" published today in the New England Journal of Medicine, researchers from the Legacy's Steven A. Schroeder National Institute for Tobacco Research...

2011-06-17 06:37:04

(Ivanhoe Newswire) -- People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, according to this study. The findings raise concerns not only about the mist inhaler- a device that delivers a soluble form of the medication tiotropium- but also about the drug itself. The mist inhaler isn't approved in the U.S., but the drug in its powdered form is commonly used to treat...

2011-06-16 08:00:00

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established,...

2011-05-24 05:03:00

CAMBRIDGE, Mass. and ST. PAUL, Minn., May 24, 2011 /PRNewswire/ -- Radius Health, Inc. ("Radius") and 3M Drug Delivery Systems ("3M") today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis. The BA058 Microneedle Patch will use 3M's patented Microstructured Transdermal System microneedle technology to administer BA058 through the...

2011-05-18 09:15:00

REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented detailed efficacy and safety results today from the Company's phase 2b study of PT003 (GFF MDI) in patients with moderate-to-very severe COPD during a late-breaker poster session at the annual meeting of the American Thoracic Society (ATS). PT003 is a proprietary fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (FF), an established,...

16f6f3708d76ec7c8a74e51fe5ef48bf
2011-05-13 07:57:28

Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal. This study is the first to assess the effectiveness of using a nicotine-free inhaler to help stop smoking. The research, which was carried out by scientists at the Università di Catania in Italy, analyzed 120 people who were enrolled in a program to help them quit smoking. The participants were split into two groups, with...

2011-05-05 08:00:00

REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. made three presentations at the Respiratory Drug Delivery Europe (RDD Europe 2011) meeting in Berlin this week elucidating the tunability, versatility and universality of the Company's porous particle-based metered dose inhaler (MDI) development approach. The data provides details of Pearl's products and novel cosuspension platform, which facilitates forming stable MDI suspensions containing respiratory drugs as...

2011-04-29 08:00:00

REDWOOD CITY, Calif., April 29, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society (ATS). PT003 (GFF-MDI) is a proprietary, fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, an established, long-acting...

2011-04-01 08:21:30

By Helena Pujol, Ivanhoe Health Correspondent (Ivanhoe Newswire) "“  A new treatment is helping sufferers of  Chronic Obstructive Pulmonary Disease (COPD) find relief in the form of a hand-held device to inhaled medication. The SPIRIVA HandiHaler is the first once-daily steroid free treatment that reduces the worsening of symptoms (exacerbations) in people with COPD, and can help manage the disease long term. "In the United States, 12 million people have been diagnosed with...


Latest Metered-dose inhaler Reference Libraries

Nicotine Replacement Therapy
2013-03-04 16:06:28

Nicotine replacement therapy is the administration of nicotine by other means than smoking. This change in the way nicotine is delivered prevents the harmful effects of smoking and is usually used in smoking cessation. Types Nicotine replacement therapy can be administered in several forms. The type used depends on the patient and what fits into their lifestyle best. The forms available include: Nicotine patches – transdermal (through the skin) Nicotine gum – orally (through the...

More Articles (1 articles) »
Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'